Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis
NCT ID: NCT06025903
Last Updated: 2024-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
140 participants
OBSERVATIONAL
2021-09-20
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance
NCT03052595
Mitochondrial Dysfunction and Disease Progression
NCT02549703
Neural Stem Cell Transplantation in Multiple Sclerosis Patients
NCT03269071
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
NCT06592703
The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis
NCT06290453
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary Progressive multiple sclerosis
patients affected by primary progressive multiple sclerosis
No interventions assigned to this group
Relapsing Remitting multiple sclerosis
patients affected by primary progressive multiple sclerosis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient able to provide informed consent
Exclusion Criteria
* Patients not affected by primary progressive or relapsing remitting multiple sclerosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Socio Sanitaria Territoriale della Valle Olona
OTHER
IRCCS San Raffaele
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Melissa Sorosina
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Melissa Sorosina
Role: PRINCIPAL_INVESTIGATOR
IRCCS San Raffaele
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS San Raffaele
Milan, MI, Italy
ASST della Valle Olona - Ospedale di Gallarate
Gallarate, VA, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MitoMS_GR-2019-12368672
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.